Clinical Trial Search

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale

Primary: tDCS Engagement of DLPFC Activity Indexed by fMRI BOLD Imaging

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: The State Social Paranoia Scale (SSPS) — 9.72; 3.90 The change score of SSPS (pre - post) — p=0.023

Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088

Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants

Primary: Genetic Linkage — 5.2 log (odds ratio) — p=<0.001

Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses

Primary: Error Percentage in Antisaccade Task — 22.6; 29.1 Error Percentage in Antisaccade Task — p=<0.05

Primary: PANSS Total — 77.9; 80 units on a scale — p=0.02

Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30

Primary: Change in Auditory Hallucination Rating Scale (AHRS)Score From Baseline to Day 5 — -6.38; -8.54 units on a scale — p=0.48

Primary: Wisconsin Card Sort Percent Perseverative Errors (Standard Score) — 87.54; 87.88; 91.80 standard score units — p=<.97

Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145

Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale

Primary: Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 52 — 50.65; 58.71; 5.35; 5.96 units on a scale — p=0.8595

Primary: Onset of Psychosis — 10; 14 percentage of sample converting

Primary: Effects of Nicotine Patch Compared With Placebo in Non- Smokers With Schizophrenia and Control Groups on Attention Measured by the Continuous Performance Test Identical…

Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…

Primary: Cognitive Performance — 76.7; 75.5; 67.2; 77.1 percentage correct of all trials

Primary: Cerebral Glutamate Levels — -1.434662171; -1.933853656; -1.412294235; -1.838991525 relative unit (RU as compared to water)

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935

Primary: Change in Biomarkers of Treatment Response: Dorsal Caudate (DCA) Gamma Amino Butyric Acid (GABA) Levels — -0.65; .0037 institutional units — p=<0.01

Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)

Primary: Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) — 87.30; 87.30; 88.46; 89.23 units on a scale — p=< .05

Primary: Total Plasmalogen Levels in the Lipid Profile — 57.65; 59.57; 75 nmoles/gram — p=0.0149

Primary: Mismatch Negativity (MMN) Amplitudes in Microvolts — -0.59; -1.19; -0.41; -0.65 microvolts

Primary: UCSD Performance-based Skills Assessment Total Score (Measures Functional Capacity) — 82.7; 84.4 units on a scale

Primary: Changes in Brain Redox State — -0.269; -0.485 ratio